A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes

• Status: Completed
• Trial end date: 2021-05-27
• Target enrollment: 0
• Participant gender: All

Summary

In this study, participants with type 1 diabetes (T1D) will take the study drug LY900014 and insulin degludec. The reason for this study is to evaluate the amount of time with glucose values within target range.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Insulin

Criteria

Inclusion Criteria:

• Participants must have type 1 diabetes and have been treated with insulin therapy for at least 1 year

• Participants must be using Continuous Glucose Monitoring (CGM) with total CGM use ≥ 2 months in the prior 6 months

• Participants must have been on the same type of short acting insulin (Humalog U-100, Novolog, Admelog, or Apidra) for at least 30 days prior to screening

• Participants must have been treated with long-acting insulin degludec U-100 for at least 30 days prior to screening

Exclusion Criteria:

• Participants must not have had more than 1 emergency room visit or hospitalization due to poor glucose control within 6 months before screening

• Participants must not have had more than 1 episode of severe hypoglycemia within the last 90 days prior to screening

• Participants must not be taking certain diabetes medications that are not allowed for study participation